A practical guide for mutational signature analysis in hematological malignancies

Analysis of mutational signatures is becoming routine in cancer genomics, with implications for pathogenesis, classification, prognosis, and even treatment decisions. However, the field lacks a consensus on analysis and result interpretation. Using whole-genome sequencing of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and acute myeloid leukemia, we compare the performance of public signature analysis tools. We describe caveats and pitfalls of de novo signature extraction and fitting approaches, reporting on common inaccuracies: erroneous signature assignment, identification of localized hyper-mutational processes, overcalling of signatures. We provide reproducible solutions to solve these issues and use orthogonal approaches to validate our results. We show how a comprehensive mutational signature analysis may provide relevant biological insights, reporting evidence of c-AID activity among unmutated CLL cases or the absence of BRCA1/BRCA2-mediated homologous recombination deficiency in a MM cohort. Finally, we propose a general analysis framework to ensure production of accurate and reproducible mutational signature data.Mutational signature analysis provides important information about the mutational processes underpinning different stages of tumorigenesis. Here, the authors compare publicly available signature extraction tools and suggest a framework for the generation of accurate and reproducible signature data.

[1]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[2]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[3]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[4]  M. Stratton,et al.  Clock-like mutational processes in human somatic cells , 2015, Nature Genetics.

[5]  Steven A. Roberts,et al.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.

[6]  Eve Shinbrot,et al.  Mutation signatures reveal biological processes in human cancer , 2016, bioRxiv.

[7]  M. Stratton,et al.  Universal Patterns of Selection in Cancer and Somatic Tissues , 2018, Cell.

[8]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[9]  E. Pinatel,et al.  Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines , 2017, Leukemia.

[10]  Gordon Cook,et al.  Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[12]  J. Carpten,et al.  Clonal competition with alternating dominance in multiple myeloma. , 2012, Blood.

[13]  M. Stratton,et al.  The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature , 2018, Nature Communications.

[14]  Serena Nik-Zainal,et al.  Mechanisms underlying mutational signatures in human cancers , 2014, Nature Reviews Genetics.

[15]  Peter J. Campbell,et al.  Population dynamics of normal human blood inferred from somatic mutations , 2018, Nature.

[16]  Andrew Menzies,et al.  ascatNgs: Identifying Somatically Acquired Copy‐Number Alterations from Whole‐Genome Sequencing Data , 2016, Current protocols in bioinformatics.

[17]  M. Stratton,et al.  Deciphering Signatures of Mutational Processes Operative in Human Cancer , 2013, Cell reports.

[18]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[19]  J. Weill,et al.  DNA polymerases in adaptive immunity , 2008, Nature Reviews Immunology.

[20]  Julian Gehring,et al.  SomaticSignatures: inferring mutational signatures from single-nucleotide variants , 2014, bioRxiv.

[21]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[22]  E. Birney,et al.  A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.

[23]  T. Chevassut,et al.  The Genetic Architecture of Multiple Myeloma , 2014, Advances in hematology.

[24]  Martin A. Nowak,et al.  Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.

[25]  G. Parmigiani,et al.  Heterogeneity of genomic evolution and mutational profiles in multiple myeloma , 2014, Nature Communications.

[26]  P. Campbell,et al.  EMu: probabilistic inference of mutational processes and their localization in the cancer genome , 2013, Genome Biology.

[27]  Peter J. Campbell,et al.  Chromothripsis and Kataegis Induced by Telomere Crisis , 2015, Cell.

[28]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[29]  David Jones,et al.  cgpCaVEManWrapper: Simple Execution of CaVEMan in Order to Detect Somatic Single Nucleotide Variants in NGS Data , 2016, Current protocols in bioinformatics.

[30]  Hans Clevers,et al.  Tissue-specific mutation accumulation in human adult stem cells during life , 2016, Nature.

[31]  Gordon Cook,et al.  APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma , 2014, Nature Communications.

[32]  F. Camargo,et al.  Somatic Mutations Reveal Lineage Relationships and Age-Related Mutagenesis in Human Hematopoiesis , 2018, Cell reports.

[33]  Pingping Qu,et al.  1 Identification of Novel Mutational Drivers Reveals Oncogene Dependencies In Multiple Myeloma . Short title : Oncogene dependencies in myeloma , 2018 .

[34]  Ville Mustonen,et al.  The repertoire of mutational signatures in human cancer , 2018, Nature.

[35]  A. Valencia,et al.  Non-coding recurrent mutations in chronic lymphocytic leukaemia , 2015, Nature.

[36]  K. Basso,et al.  Germinal centres and B cell lymphomagenesis , 2015, Nature Reviews Immunology.

[37]  P. A. Futreal,et al.  MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data , 2016, Genome Biology.

[38]  A. Børresen-Dale,et al.  The Life History of 21 Breast Cancers , 2012, Cell.

[39]  Catherine J. Wu,et al.  Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia. , 2015, Blood.

[40]  N. Tretyakova,et al.  Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers , 2002, Oncogene.

[41]  R. Houlston,et al.  Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms , 2018, Leukemia.

[42]  Alain Viari,et al.  Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency. , 2017, Cancer research.

[43]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[44]  James X. Sun,et al.  Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition? , 2018, Leukemia.

[45]  Dmitry A. Gordenin,et al.  Hypermutation in human cancer genomes: footprints and mechanisms , 2014, Nature Reviews Cancer.

[46]  A. McKenna,et al.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.

[47]  Edwin Cuppen,et al.  MutationalPatterns: comprehensive genome-wide analysis of mutational processes , 2016, Genome Medicine.

[48]  Genomic landscape and chronological reconstruction of driver events in multiple myeloma , 2018 .

[49]  G. Mills,et al.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer , 2012, British Journal of Cancer.

[50]  S. Lonial,et al.  Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. , 2010, Blood.

[51]  L. Rassenti,et al.  Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. , 1998, The Journal of clinical investigation.

[52]  B. Taylor,et al.  deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution , 2016, Genome Biology.

[53]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[54]  M. Stratton,et al.  Mutational signatures associated with tobacco smoking in human cancer , 2016, Science.

[55]  Teresa M. Przytycka,et al.  Detecting presence of mutational signatures in cancer with confidence , 2017, bioRxiv.

[56]  E. Birney,et al.  HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures , 2017, Nature Medicine.

[57]  N. Munshi,et al.  Genetics of multiple myeloma: another heterogeneity level? , 2015, Blood.

[58]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[59]  S. Nik-Zainal,et al.  Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancer , 2017, Science.

[60]  Steven A Roberts,et al.  Clustered and genome‐wide transient mutagenesis in human cancers: Hypermutation without permanent mutators or loss of fitness , 2014, BioEssays : news and reviews in molecular, cellular and developmental biology.

[61]  B. Walker,et al.  Knick-knack PADIMAC. , 2018, Blood.

[62]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[63]  S. Gabriel,et al.  Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution , 2015, Nature Communications.

[64]  L. Pasqualucci,et al.  BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Rafael Rosales,et al.  signeR: an empirical Bayesian approach to mutational signature discovery , 2017, Bioinform..

[66]  Keith A. Boroevich,et al.  Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer , 2016, Nature Genetics.

[67]  N. Munshi,et al.  Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. , 2011, Blood.

[68]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[69]  R. Greil,et al.  APOBEC3 signature mutations in chronic lymphocytic leukemia , 2014, Leukemia.

[70]  P. Campbell,et al.  Genomic patterns of progression in smoldering multiple myeloma , 2018, Nature Communications.

[71]  Keiran M Raine,et al.  cgpPindel: Identifying Somatically Acquired Insertion and Deletion Events from Paired End Sequencing , 2015, Current protocols in bioinformatics.

[72]  L. Pasqualucci,et al.  Expression of the AID protein in normal and neoplastic B cells. , 2004, Blood.